(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma

por Malenge, Marion M., Patzke, Sebastian, Ree, Anne H., Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada H.V.
Publicado 2020

Anti-CD37 radioimmunotherapy with (177)Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro

por Malenge, Marion M., Maaland, Astri Fjelde, Repetto-Llamazares, Ada, Middleton, Brian, Nijland, Marcel, Visser, Lydia, Patzke, Sebastian, Heyerdahl, Helen, Kolstad, Arne, Stokke, Trond, Ree, Anne Hansen, Dahle, Jostein
Publicado 2022